Anastrozole Arimidex Powder

Anastrozole Arimidex Powder Quick Details:

Arimidex is generally the modern preferred anti-estrogen in breast cancer treatment, as well as the preferred AI in low testosterone treatment plans. For the anabolic steroid user, it is highly efficient and should be the only AI you need. However, in cases where gynecomastia symptoms are already beginning to show, many report heavy Letrozole doses to be the answer to the remedy, where in time switching to Arimidex as a preventative measure.

Anastrozole Arimidex Powder Functions & Traits:

The functions and traits of Arimidex although powerful are extremely simple. As an AI Arimidex functions by blocking the aromatase enzyme, which is in turn responsible for the production of estrogen. By inhibiting the aromatase process, Arimidex will lower the body’s serum estrogen levels; in fact, a total suppression of estrogen by 80% has been well noted with this AI. This will prove very beneficial to numerous breast cancer patients and extremely valuable to many anabolic steroid users.

Arimidex also has the ability to stimulate the release of Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH), two hormones essential to natural testosterone production. This has led some physicians to use the AI in low testosterone treatment plans in place of testosterone, but it’s generally not the best choice. Arimidex in a low testosterone plan is generally better served in conjunction with testosterone therapy.

Benefits of Anastrozole Arimidex Powder:

The ATAC study found that 5 years of Arimidex is better than 5 years of tamoxifen as the first hormonal therapy for postmenopausal women with early-stage, hormone-receptor-positive breast cancer. Arimidex is better than tamoxifen for:

increasing the time before the cancer comes back in those who experience recurrence
reducing the risk of the cancer spreading to other parts of the body
reducing the risk of a new cancer developing in the other breast
Research presented at the 2013 San Antonio Breast Cancer Symposium showed that Arimidex can lower the risk of first-time, hormone-receptor-positive breast cancer in postmenopausal women at high risk who haven’t been diagnosed. Arimidex isn’t approved by the FDA for this use, but doctors may consider it a good alternative to other hormonal therapies approved to reduce risk in high-risk women.

Related Products: Clomifene Citrate, Tamoxifen Citrate, Letrozole, Exemestane etc.

For more details, plz contact us freely,  thanks for your kind attention. 🙂